| abstract |
(57) [Summary] Formula (I) [Wherein R contains 1 or 2 heteroatoms selected from the group consisting of halogen, nitro, lower acyloxy, trifluoromethoxy, cyano, C 3 -C 5 -cycloalkyl or O, S and N , unsubstituted or substituted C 3 -C 6 - mono by heteroaryl -, di - or tri-substituted C 2 -C 7 - alkyl; or unsubstituted respectively, or halogen, nitro, lower acyloxy, trifluoromethoxy, cyano , C 3 -C 5 - mono by heteroaryl - - cycloalkyl or O, containing one or two heteroatoms selected from the group consisting of S and N, unsubstituted or substituted C 3 -C 6, di - or C 3 -C 7 are trisubstituted - alkenyl or C 3 -C 7 - alkynyl; other symbols are as defined in claim 1 In represented by α- hydroxamic acid derivatives are described. These compounds are MMP and in particular MMP2 inhibitors and are MMP dependent diseases, in particular inflammatory diseases, rheumatoid arthritis, osteoarthritis, tumors (tumor growth, metastasis, progression or wetting) and lung diseases (eg emphysema) , COPD) treatment. |